-
PIL have done a lot of prep work over several years, and are finally looking like they might have a better mousetrap. The company has hired a new CEO who has knowledge of and connections in the US healthcare market. Who knows where this one will go, but arthritis, and inflammation generally, is a huge potential market so might be worth a punt.
Disc, have a few, not worth much though.
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks